Monthly Archives: July 2017

Success and Succession

By | July 26, 2017

It is with gratitude and humility that I write this post marking the end of my term as Chapter President. Leading the largest Chapter through a year of surpassing excellence has taught me much and left me in awe of what can be accomplished by committed, well-organized volunteers. Some numbers: 1,700 members, spread over 80,000… Read More »

Student Members Earn Chapter Scholarships

By | July 26, 2017

The Chapter is proud to award $12,500 in scholarships to the following winners of the June 2017 round of the Joel Goldenberg Memorial Scholarship Program: Adam Blackwell, UMass Amherst John de la Parra, Northeastern University Michael Doane, UMass Lowell Chelsea Fox, University of Rhode Island Jamie Freud, Worcester Polytechnic Institute Daniel Kallin, UMass Amherst Aislinn… Read More »

Avecia Expanding Drug Manufacturing Facility in Milford

By | July 19, 2017

Avecia, a pharmaceutical manufacturer in Milford, says it is building what will become the largest manufacturing site in the world for a specialized drug ingredient called oligonucleotide. The expansion, which will add 20,000 square feet of space, will more than double the Milford site’s total capacity, the company said in a recent announcement. Oligonucleotide, a… Read More »

MassBioEd Predicts Job Trends Forecast for the Biopharma Industry

By | July 19, 2017

The MassBioEd Foundation released its 2017 Annual Job Trends Forecast at Life Sciences Workforce 2017, its second annual conference on life sciences workforce trends.  The event was held at Northeastern University and featured twenty-seven industry and higher education speakers, as well as Lt. Governor Karyn Polito, who provided keynote remarks. The Forecast included the following… Read More »

Novartis Gene Therapy Recommended for Approval by FDA Advisory Committee

By | July 17, 2017

Novartis has announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has relapsed or resisted treatment (r/r). A Biologics License Application (BLA) for this… Read More »

What is Novartis CAR-T Therapy?

By | July 17, 2017

CAR-T (chimeric antigen receptor T cell) therapy is different from typical small molecule or biologic therapies because it is manufactured for each individual patient using their own cells. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in a manufacturing facility to create T cells that are genetically coded to… Read More »

Alnylam and Sanofi Genzyme Report Strong Results from Phase 2 Trial of RNAi Treatment for Hemophilia

By | July 12, 2017

Alnylam and Sanofi Genzyme have announced new positive results from the ongoing Phase 2 study with fitusiran in patients with hemophilia A and B, with or without inhibitors. Fitusiran is an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of patients with hemophilia A and B, that is designed to lower levels of AT… Read More »

Novartis Phase 3 Trial Shows Anti-Inflammatory Drug Reduces Cardiovascular Risk

By | July 12, 2017

Novartis has announced topline results from the global Phase 3 CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination with standard of care in people with a prior heart attack and inflammatory atherosclerosis. With more than 10,000 patients enrolled in the study over the last six years, CANTOS is one of… Read More »